Systasy is a next-generation biopharma company pioneering a transformative approach to drug discovery, with a specific focus on complex brain diseases—one of the most pressing medical challenges of our time, impacting nearly one billion people globally.

Originating as a spin-off from the Max Planck Institute, Systasy has engineered a powerful, modular platform that integrates patient-derived disease models, real-world clinical data, human brain simulations, and industrial-scale, multiplexed screening technologies. This combination enables a deep, mechanistic understanding of multifactorial brain disorders and unlocks entirely new therapeutic opportunities.

What sets Systasy apart is its proprietary DNA barcoding technology, which fuses granular clinical and genomic patient data with stem cell-derived disease models. This allows for high-throughput, scalable analysis of disease biology across diverse patient populations—shedding light on drug mechanisms of action, enabling patient stratification, and informing precision therapies. Combined with pathway-centric screening and machine learning-driven analytics, the platform continuously evolves, learning from every dataset to refine hypotheses, optimize targets, and de-risk clinical development.

Systasy’s platform spans the entire drug development value chain—from target discovery to biomarker identification and patient segmentation—dramatically reducing costs, attrition rates, and time to market. Already generating seven-digit revenues, the company is rapidly expanding its capabilities through automation and AI integration, creating a self-reinforcing engine for therapeutic innovation.

In parallel, Systasy is driving co-discovery partnerships with leading pharma and biotech players, accelerating the development of safer, more effective drugs. Mature discovery programs are spun out into independent ventures. One such spin-out is already developing a curative therapy for stroke, targeting a $5.8B global market.

Systasy is now raising Series A funding to scale its platform, accelerate proprietary and partnered programs, and expand its commercial footprint. With its integrative science, proprietary technology, and growing revenue base, Systasy is uniquely positioned to transform drug development for some of the most difficult diseases of our generation.